Search results
A therapeutic agnostic injection safety device. Designed to improve the patient injection experience with a goal to increase medication adherence and limit the development, expense, and regulatory burdens of injectable products.
We know the problems that patients face with injection medications. We’ve seen it firsthand with our families and our patients. Revolutionizing this process to give patients control over their medications is our mission. Patients deserve a better experience.
CAUTION – Investigational device. Limited by Federal law to investigational use. © Copyright 2022 – Love Lifesciences | Website by Screamin Cow Design Studio
12 wrz 2024 · Love Lifesciences company profile. Developer of hybrid injection devices for medication delivery. 2021 • Overland Park (United States) • Seed. Last updated: September 12, 2024. Love Lifesciences Key Metrics. Total Funding. $724K. in 2 rounds. Latest Funding Round. $600K. Seed, Jun 21, 2023. Ranked. 25 th. among 41 active competitors.
Love Lifesciences develops medical devices in the medication administration and medication adherence spaces. Love Lifesciences has two lead products: UniPen a single use injection device targeted at improvements to the injection experience for patients with reduced financial and time burdens for pharma integration and MultiPen a multi-dose.
Biotechnology. Overland Park, Kansas 413 followers. A Lifesciences company developing injection devices to revolutionize the patient experience and improve health outcomes. View all 3 employees....
6 dni temu · Regulation FD Disclosure. On October 11, 2024, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited, each direct, wholly owned subsidiaries of Wave Life Sciences Ltd. (collectively, “Wave”) were notified by Takeda Pharmaceutical Company Limited (“Takeda”) that Takeda did not intend to exercise and therefore elected to ...
